In this group, progression-free survival was a median of 4.4 months among those on pemetrexed, compared with 1.8 months among those on placebo, according to the prescribing information.

• 据处方信息，在该研究中，中位无进展生存期培美曲赛组为4.；4个月，对应安慰剂组为1